FyMed, Inc

FyMed Announces Top-Line Results Demonstrating Superiority of FY103B over Celecoxib in the Treatment of Pain and Inflammation

LogoFyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, today announced successful completion of studies for FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. FY103B demonstrated superior therapeutic effects in the management of acute and chronic pain and inflammation, and was found to be significantly superior to celecoxib in terms of efficacy and safety.